Clinical Trials
34 trialsRadiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
ARCH
University of Colorado, Denver
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
Astellas Pharma Inc
2F
Ente Ospedaliero Ospedali Galliera
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
Alliance for Clinical Trials in Oncology
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
Canadian Cancer Trials Group
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer
Dana-Farber Cancer Institute
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
Canadian Cancer Trials Group
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
UNICANCER
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
Radiation Therapy Oncology Group
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Canadian Cancer Trials Group
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Radiation Therapy Oncology Group
Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
National Institutes of Health Clinical Center (CC)
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
M.D. Anderson Cancer Center
IAS
University of Washington
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
University of Washington
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Radiation Therapy Oncology Group
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Mayo Clinic
Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate
Alliance for Clinical Trials in Oncology
Hormone Therapy in Treating Patients With Prostate Cancer
Alliance for Clinical Trials in Oncology
Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c
Takeda
Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer
Takeda
Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
National Cancer Institute (NCI)
Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
University of Chicago
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
SWOG Cancer Research Network
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)